Another piece of bad news has come out for St. Jude Medical (NYSE: STJ) regarding an FDA report on defibrillator lead Durata, bringing shares down 12%. In this video, Motley Fool health-care analyst David Williamson talks about how these findings add to a recent string of product difficulties for St. Jude, and how, as an investor, if you see this as the company turning a corner, then it could be a cheap entry point.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.